In this issue of Clinics in Liver Disease, guest editor Dr. Steven L. Flamm brings his considerable expertise to the topic of Updates in Consultations in Liver Disease. Many disease entities are uncommon and complicated in scope, and liver disease may occur in the setting of other chronic medical conditions and involve other organ systems. In this issue, top experts provide a up-to-date framework for approaching consultation for common liver-related problems for the gastroenterology and hepatology practitioner. Contains 12 practice-oriented topics including clinical pearls in evaluation and treatment of patients with liver disease; evaluation of patients with markedly elevated liver enzymes; evaluation of liver disease in pregnancy; COVID and implications on the liver; and more. Provides in-depth clinical reviews on consultations in liver disease, offering actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

An essential resource for the day-to-day management of patients with liver disease and its complications. Covering conditions commonly seen in practice, such as hepatitis, nonalcoholic fatty liver disease, auto-immune disease, and a host of other hepatic problems, this book provides a practical reference for clinicians and trainees involved in the care of patients with diseases of the liver. Each chapter is written by an international expert in the field of hepatology and presents an evidence-based review of the disease or problem with a systematic approach to diagnosis and management. It provides clear illustrations, algorithms, and tables for easy access to key information. Practical Management of Liver Diseases will help to ensure that healthcare professionals are up to date on recent advances to detect and treat these diseases rapidly and efficiently for maximum patient benefit.

In this issue of Critical Care Nursing Clinics, guest editor and clinical nurse specialist Cynthia Benz brings her considerable expertise to the topic of Care for the Liver Failure Patient. Nurse involvement in chronic and fatal liver diseases requires interventions to improve symptom control, reduce inpatient care, prevent worsening of condition, and improve quality of life. In this issue, top experts focus on these nursing interventions for patients experiencing liver failure or the eventuality of liver failure. Contains 11 practice-oriented topics including acute liver failure in the pediatric patient; right sided heart failure and liver failure; hepatocellular carcinoma; ascites; esophageal varices; and more. Provides in-depth clinical reviews on care for the liver failure patient, offering actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

Cardio-Hepatology: Connections Between Hepatic and Cardiovascular Disease provides a direct relationship between the cardiac and hepatic pathologies providing the link between the heart and liver and showing how liver diseases predispose to impairment in heart functioning and vice versa. Considering the growing number of patients living (and living longer) with heart failure and/or congenital heart disease, it is important to know when and how to test for liver disease in this population, how to interpret abnormal test results, and what management is appropriate. Coverage includes what should be done for patients to limit, avoid, or postpone the impairment in the liver functioning induced by heart diseases and the impairment in the heart functioning induced by liver diseases, on the basis of scientific-exposed evidence and pathophysiology knowledge. This comprehensive, extended review of the medical literature is perfect for researchers interested in the connection between cardiology and hepatology as well as clinicians making therapeutic decisions for patients suffering from heart or liver chronic diseases.

Chronic Hepatitis C Virus: Lessons from the Past, Promise for the Future documents the monumental advances that have been made in our understanding of chronic HCV during the past decade. The first section reviews the natural history of chronic HCV, how this virus can affect other organs in addition to the liver, and whether treating chronic HCV alters the natural history of this disease. Section 2 reviews the advances that have been made in the treatment of chronic HCV during the past decade with interferon based therapy. Separate chapters on response guided therapy and how to manage the adverse events associated with these medications provide the physician with the concepts required to more effectively treat chronic HCV now and in the future. As the genetics of virologic response have recently been elucidated, a chapter is devoted to helping the clinician understand how genes that modulate disease processes and their treatment are identified and utilized in clinical care. Section 3 deals with the future of HCV treatment and specific inhibitors of HCV. Specific chapters explain how targets for drugs are identified and how drugs are then developed and tested; how mutations of HCV develop and how anti-viral agents will affect this process; the most up to date data regarding the treatment of chronic HCV with peginterferon, ribavirin and anti-viral agents; and the potential to treat chronic HCV with just oral anti-viral agents and without peginterferon and ribavirin in the future. The final section of this book covers issues related to liver transplantation in patients with chronic HCV. Separate chapters review the natural history of chronic HCV in liver transplant recipients and the impact of utilizing HCV positive donors. The volume concludes with chapters that cover the treatment of chronic HCV both prior to and after liver transplantation with potent anti-viral agents. Chronic Hepatitis C Virus: Lessons from the Past, Promise for the Future is a valuable resource for all physicians caring for patients with chronic HCV.

Alcohol and other drugs of abuse are major contributing factors to liver disease and its pathology. Alcoholic cirrhosis causes thousands of deaths each year in the United States, and encourages liver replacement. A better understanding of the mechanisms of liver pathology will significantly aid basic researchers and physicians in treating and preventing liver damage. This book is designed especially for those researchers wishing to understand alcoholic liver disease. Therefore the role of alcohol in changing nutrition and its nutritional effects on liver disease are reviewed. The generation of free radicals during alcohol use has been found to be an important cause of membrane changes, of cancer development, and of lipid alterations-and thus of liver pathology. In addition to alcohol, other drugs of abuse, including morphine, cocaine, marijuana, and caffeine have also been shown to be significant contributors to liver pathology. The prevalence of drug and alcohol use and abuse today means that liver disease will continue as a major social and medical problem. The explanation of its biological origins cannot fail to help us better understand and treat the disease in the years to come.

This book helps scientists, clinicians and other interested individuals understand recent clinical advances and challenges for the future. It covers many basic aspects of the pathogenesis of chronic hepatitis C, HCV infections in particular populations, approaches to therapy, and prevention and control of HCV Infection. The book provides a succinct review of the large amount of data generated by multiple groups over the past two decades that has revealed the natural history of HCV infection. Similarly, it summarizes current understanding of the origins of HCV-associated hepatocellular carcinoma, cirrhosis and hepatic fibrosis. Extra-hepatic manifestation and metabolic disorders related to HCV infection are described. In this volume, these clinically important aspects of HCV infection are comprehensively described. Highlights are description of newly developed direct- acting antivirals. The authors represent a worldwide distribution of leaders in the field reflecting the global nature of HCV infection. Based on recent data concerning the genetic- and geographical diversity of HCV, and increased global disease burden of HCV infection, challenges for global control of HCV infections are described.

This book is the proceedings of the Falk Symposium No.156 on ?Genetics in Liver Disease?, part of the XIII International Liver Week 2006 held in Freiburg, Germany, 7 October 2006. The first section covers the basic aspects of genetic diagnosis, pharmacogenetics, micro-arrays and their relevance for liver diseases, including viral hepatitis, hepatocellular carcinoma, and gallstone diseases. In the second section, the most important hereditary liver diseases are discussed, including haemchromatosis, Wilson disease, alpha-1-antitrypsin deficiency, porphyrias and cystic fibrosis. In the third section, the genetics of cholestatic and metabolic liver diseases as well as the current status of experimental and clinical studies of gene therapy for liver diseases and stem cell transplantation are presented. Each section starts with a State-of-the-Art Lecture which introduces the topic. In the tradition of the Falk Symposia, this book provides an exciting overview of the current developments in the field of genetics of liver diseases, their diagnosis, treatment and prevention, presented by an international array of outstanding scientists and clinicians.

Pregnancy is the main determinant of some liver diseases in humans: acute fatty liver of pregnancy, cholestasis of pregnancy, and acute liver failure in toxaemia of pregnancy. Pregnancy also modifies the natural history of other more common hepatobiliary diseases, such as cholesterol gallstones. Sex hormones (mainly oestrogens, progesterone and/or some of its metabolites) and prolactin are considered responsible for these pathological consequences and they also appear to be influential in the outcome of several other hepatobiliary disorders, in both sexes and all ages. Although these disorders and their hormonal interrelations have been clinically well characterized, their pathogenesis remains obscure from the biomolecular point of view. In recent years, novel approaches using new technologies have improved our understanding of hormone actions and metabolism, hormone receptors, metabolic pathways and their interrelations with closely related molecules, such as bile acids. This book, the proceedings of the 89th Falk Symposium, held in Santiago, Chile, 10-11 November, 1995, will help research scientists and clinicians to review basic and clinical aspects of these interactions, in order to stimulate biomedical research in a relevant and exciting area.

In collaboration with Consulting Editor, Dr. Norman Gitlin, Guest Editors Drs. Andres Cardenas and Thomas Reiberger have created an up-to-date monograph on the complications of cirrhosis. They have secured top experts to contribute clinical review articles on the following topics: Non-invasive Detection of CSPH in cACLD; Prevention of First Decompensation in ACLD; Treatment of Acute Variceal Bleeding in 2020: When to Use TIPS; Prevention of Variceal Bleeding and Rebleeding by NSBB: A Tailored Approach; The Role of Hepatic Venous Pressure Gradient (HVPG); Measurement in the Management of Cirrhosis; Bacterial Infections in Cirrhosis as a Cause or Consequence of Decompensation; Nutrition in Chronic Liver Disease; Diagnosis and Management of Hepatic Encephalopathy; Discriminating Acute Decompensation from Acute-on-Chronic Liver; Management of Severe and Refractory Ascites; Monitoring Renal Function and Therapy of HRS patients with Cirrhosis; Coagulopathy in Cirrhosis; and Current Concepts of Cirrhotic Cardiomyopathy. Hepatologists will come away with the information they need to manage these patients.

During the last decade, knowledge about cholestatic liver disease and concomitant diseases, such as ulcerative colitis, cholangio- and hepatocellular carcinoma, pancreas and colon cancer, has increased considerably. Studies on ursodeoxycholic acid treatment alone or in combination with immunosuppressive compounds and their positive effects on biliary liver disease as well as on so-called overlap syndromes or intestinal tumors are published in increasing numbers, and stimulate discussion on whether or not ursodeoxycholic acid is able to improve the general condition and/or life expectancy of patients. On the other hand, genetics, aetiological and pathogenetic aspects are still difficult to comprehend, but are the absolute prerequisite for the development of better treatment options. This book is the proceedings of Falk Symposium No. 136 (Part I of the XII Falk Liver Week, held in Freiburg, Germany, on October 15-16, 2003), and contains stimulating, exciting and controversial papers on clinical and also basic research at the highest scientific level.

Now fully revised to include recent advances in the field, the third edition of Gastrointestinal and Liver Pathology Pathology, a volume in the Foundations in Diagnostic Pathology series, is an essential foundation text for residents and pathologists. The popular template format makes it easy to use, and new information throughout brings you up to date with what's new in the field, including advances in molecular diagnostic testing and new diagnostic biomarkers. Practical and affordable, this resource is ideal for study and review as well as everyday clinical practice.Key features of this practical text include:  A consistent, user-friendly format that explores each entity's clinical features, gross and microscopic findings, ancillary studies, differential diagnoses, and prognostic and therapeutic considerations.  A focus on specific features of selected neoplastic and non-neoplastic entities, including broad and in-depth differential diagnoses.  Clinical information on treatment and prognosis, enabling you to better understand the clinical implications of the diagnosis.  Nearly 1,000 full-color, high-quality illustrations with extensive figure legends, as well as abundant boxes and tables throughout.  Enhanced eBook version included with purchase. Your enhanced eBook allows you to access all of the text, figures, and references from the book on a variety of devices.  What's NEW in this edition:  Advances in molecular diagnostic testing and its capabilities and limitations, including targeted/personalized medicine.  New diagnostic biomarkers and their utility in differential diagnosis, newly described variants, and new histologic entities.  The latest TNM staging and WHO classification systems.  New co-editors Drs. Amitabh Srivastava and Daniela S. Allende lead a team of expert, internationally recognized pathologists who keep you up to date with the latest information in the field. 

Nonalcoholic fatty liver disease is one of the most common liver diseases worldwide affecting patients from all ages, races, and ethnic backgrounds. It comprises a spectrum of hepatic pathology ranging from simple steatosis, in which there is an increase of fat accumulation in hepatocytes, to nonalcoholic steatohepatitis and cirrhosis. The significant prevalence of this disease-between 15 and 45 percent of the general population-means that it contributes to an increased burden of ill health both today and in the future. Liver Metabolism and Fatty Liver Disease addresses the current understanding of the development of nonalcoholic fatty liver disease as well as the clinical aspects of the disease by examining the current knowledge surrounding metabolism in the liver. The book discusses various topics including the involvement of oxidative stress, metabolic effects, and inflammation as well as the effect of nutrition on the development and progression of the disease.

A cutting-edge review of the latest findings on key scientific topics and the best strategies for evaluation and management of portal hypertension in the clinic. Writing in an easy-to-read style, the authors review its pathobiology, the progress being made in its experimental understanding, the methodologies to assess it in humans, the treatment of its complications (esophageal varices, ascites, and hepatorenal syndrome), and its treatment in special circumstances (during pregnancy, in children, or when the portal vein is blocked). They also provide in-depth coverage of the pros and cons of the various therapeutic choices available to the clinician managing patients with complicated portal hypertension.

Recent advances in gastroenterology and hepatology as well as new findings in biliary and pancreatic diseases are presented in the proceedings of the 86th annual congress of the Japanese Society of Gastroenterology. From the hundreds of papers delivered at the congress, 70 were selected for inclusion here. Opening with special lectures on gastroenterology in the new millennium, ulcerative colitis-pathophysiology and therapy, and life style-related diseases and gastroenterology, the volume is divided into sections reflecting the major concerns of researchers in the science of digestive diseases in Japan today: apoptosis in digestive organs, nitric oxide, transcription factors in digestive organs, antigen-presenting cells, pathology of inflammatory bowel disease, NSAID-induced gastric lesions, microcirculation in digestive diseases, hepatic regeneration, and hepatic fibrosis.

Hepatitis delta virus which causes severe acute and chronic liver disease was discovered following the detection of a novel antigen-antibody system in hepatitis B virus carriers. Currently, HDV is classified as a subviral satellite of hepatitis B virus. However, unlike other satellite viruses, the dependence of HDV on HBV is limited solely to the provision of an envelope of hepatitis B surface antigen for virus assembly. Research into the molecular virology of the HDV life cycle has revealed a fascinating collection of biology. These insights are now beginning to be translated into new potential treatment strategies. There are currently still an estimated 15 million HDV carriers worldwide.

.

Together with Consulting Editor Dr. Alan Buchman, Drs. Arun J. Sanyal and Mohammad Siddiqui have put together a comprehensive issue devoted to fatty liver disease for the gastroenterologist. Expert authors have contributed clinical review articles on the following topics: Burden of disease due to NAFLD; Genetic risk factors and disease modifiers of NASH; How to identify the patient with NASH who will progress to cirrhosis; Similarities and Differences between cirrhosis due to NASH versus other etiologies; Impications of NASH as the etiology of end stage liver disease prior to and after liver transplantation; Why do lifestyle recommendations fail in most patients; Rational nutritional therapeutics for NAFLD; Recruitment and retention strategies in long-term trials for NASH; Managing extrahepatic comorbidities in NAFLD; The current status of noninvasive tools for the assessment of NAFLD; and Pharmacological Treatment strategies for NASH. Readers will come away with the information they need to improve outcomes in patients with fatty liver disease.

In recent years there has been an increasing need for transplantation, but the number of donor livers available has increased only slightly, despite intensive public relations activities. New concepts in the field of transplantation, for instance the transplantation of living donor organs or the splitting of organs, are urgently required, to safeguard the treatment of patients with severe liver disease. The development and clinical application of cell therapy for patients with liver disease could soon present a significant enhancement of the therapeutic options. The aim of such cell therapy is to repair or improve the biological function of the chronically and acutely damaged liver. Even though systematic trials are not available, individual case reports and small series already show promising clinical results.

Present concepts of cell therapy for liver diseases based on the use of primary hepatocytes have recently been considerably extended through new data on the biology of stem cells. The adult haematopoetic stem cell as a pool for hepatocyte grafts - what would be the perspectives for the clinical application?

This book is the proceedings of the Falk Symposium No. 126 on Hepatocyte Transplantation' (Progress in Gastroenterology and Hepatology Part III) held in Hannover, Germany, October 2-3, 2001, and is a forum for basic research, but also for questions concerning clinical applications in the field of hepatocyte transplantation.

Bile acid research has attracted increasing attention from both basic scientists and clinical hepatologists over the last decade. Experimental studies have expanded our knowledge of the role of bile acids in liver disease, and well-designed clinical trials have documented beneficial effects of bile acid treatment for a number of hepatobiliary diseases. Bile Acids in Liver Diseases, the proceedings of an International Falk Workshop held in Munich, January 1995, provides insights into current concepts in bile acid chemistry, bile acid synthesis and metabolism, and transport of bile acids across the hepatocyte. The role of bile acids in bile formation, cholestasis and hepatotoxicity are discussed. Finally, the book addresses experimental studies and hypotheses about the putative mechanisms of action of ursodeoxycholic acid in cholestatic liver diseases, and summarizes the clinical applications of bile acid treatment on the basis of controlled clinical trials.

There has been a tremendous amount of scientific progress in our understanding of the molecular mechanisms of transport processes in the liver within the last few years. Cloning of various members of organic anion and cation transporters has provided the necessary tools to study their regulation under physiological and pathophysiological conditions and has advanced our knowledge about bile formation. Mutations of various hepatic organic anion transporters have been identified in humans as hereditary defects leading to the heterogenous syndrome of progressive familial intrahepatic cholestasis (PFIC). Various mouse models including knockout animals have given us the opportunity to gain insight into lipid transport by the liver and the genetics of cholesterol gallstone formation. The physiology of bile duct cells and the molecular mechanisms leading to various cholangiopathies have been a main scientific focus in hepatology in recent years. Drug targeting to the liver by hepatic organic anion transporters represents an attractive way of selective delivery of pharmaceutical agents in humans. Ursodeoxycholic acid is successfully used in the treatment of patients with chronic cholestatic liver disease and major advances have been made in understanding its mode of action in liver and bile duct cells. This book, the proceedings of the Falk Workshop held in Aachen, Germany, on 25-26 January 2001, contains chapters on all important aspects of biliary transport by well-known experts in this field. It is an essential resource for new developments in the field of biliary transport, both in basic science and clinical medicine.

The advent of molecular biology and recombinant DNA technology has profoundly changed contemporary medicine. These new scientific tools have made it possible to identify and understand pathological mechanisms at cellular, subcellular and molecular levels which has added previously unimaginable novel dimensions to the diagnosis, therapy and prevention of a rapidly increasing number of diseases of the liver and biliary system. The title of this book - Acute and Chronic Liver Diseases: Molecular Biology and Clinics - expresses this epochal progress in hepatology. A series of acute or chronic diseases of the liver has been chosen whose modern clinical management most eloquently reflects the impact of the new scientific insight gained from molecular biology. The book, the proceedings of the 87th Falk Symposium (X International Congress of Liver Diseases: Part II of the Basel Liver Week 1995) held in Basel, Switzerland, October 19-21, 1995, first presents an overview of the molecular pathology of the chosen disease, followed by discussions of the clinical inference which this new scientific information entails for diagnosis, management and therapy. This approach is expected to ease the readers' endeavour to connect basic to clinical science and to facilitate appreciation of the enormous progress but also the inherent limitations and arising questions which modern molecular biology has brought to clinical medicine.

Highly illustrated and conveniently templated for quick reference, Atlas of Liver Pathology, 4th Edition, is a useful Atlas and text for every practicing pathologist or trainee who assesses liver biopsy specimens. From cover to cover, it contains all the information needed to identify histologic features and correlate them with clinical findings, offering a clearer understanding of the clinical implications of the disease as it relates to treatment. More than 1,200 high-quality, full-color images and illustrations provide you with a complete visual guide to the vast majority of liver diseases and assist in the diagnoses of biopsy and resected liver specimens. Provides clear, templated information for each disease: Major Morphologic Features; Special Stains; Differential Diagnoses; Clinical and Biologic Behavior; and Treatment and Prognosis.  Incorporates relevant data from ancillary techniques (immunohistochemistry, cytology, cytogenetics and molecular genetics), giving you the necessary tools required to master the latest breakthroughs in diagnostic technology.  Incorporates the latest diagnostic biomarkers and their utility in differential diagnoses, newly described variants, and new histologic entities.  Contains two new chapters on liver biopsy interpretation and autoimmune hepatitis.  Features concise, bulleted text and abundant tables that cover common as well as rare diseases, differential diagnoses, and more.  An eBook version is included with purchase. The eBook allows you to access all of the text, tables, figures and references, with the ability to search, customize your content, make notes and highlights, and have content read aloud. 

Studies on Hepatitis Viruses: Life Cycle, Structure, Functions, and Inhibition presents the latest on this systemic infection that predominantly affects the liver with inflammation that can be acute or chronic. Hepatitis viruses have been the subject of intense study in the last twenty years, with a wealth of information related to their lifecycle, structure, functions and inhibition being presented. This book compiles the most important developments and research, giving users a very useful guide on this evolving area of virology and medicinal chemistry.

Stem Cells and Cancer in Hepatology: From the Essentials to Application offers basic scientists and clinicians in the fields of stem cells, hepatology and oncology an overview of the interaction between liver biology, stem cells and cancer. It discusses how the liver performs regeneration and repair, the role stem cells play in these processes, and the mechanisms by which liver cancers are initiated and developed. As the field of stem cells and cancer stem cells in hepatology is new and dynamic, thus making it difficult for researchers and clinicians to understand the most relevant historic and novel studies, this volume addresses that challenge.

Brain Tryptophan Perturbation in Hepatic Encephalopathy: Implications for Effects by Neuropsychoactive Drugs in Clinical Practice; F. Bengtsson, et al. Hepatic Encephalopathy in Acute Liver Failure: Role of the Glutamate System; A. Michalak, et al. Glutamate and Muscarinic Receptors in the Molecular Mechanisms of Acute Ammonia Toxicity and of Its Prevention; M.D. Minana, et al. Studies on the Pharmacological Properties of Oxindole (2-Hydroxyindole) and 5-Hydroxyindole: Are They Involved in Hepatic Encephalopathy?; F. Moroni, et al. The Involvement of Ammonia with the Mechanisms That Enhance GABA-ergic Neurotransmission in Hepatic Failure; E.A. Jones, A.S. Basile. Direct Enhancement of GABA-ergic Neurotransmission by Ammonia; J.-H. Ha, et al. The Peripheral Benzodiazepine Receptor and Neurosteroids in Hepatic Encephalopathy; M.D. Norenberg, et al. Ornithine Aminotransferase as a Therapeutic Target in Hyperammonemias; N. Seiler. Sparse-Fur (spf) Mouse as a Model of Hyperammonemia: Alterations in the Neurotransmitter Systems; I.A. Qureshi, K.V.R. Rao. Abnormal Gene Expression Causing Hyperammonemia in Carnitine-Deficient Juvenile Visceral Steatosis (JVS) Mice; T. Saheki, et al. 7 Additional Articles. Index.